Ensysce Biosciences Inc (ENSC) - Total Assets
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) holds total assets worth $2.17 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Ensysce Biosciences Inc to assess how comfortably operating cash covers total debt obligations.
Ensysce Biosciences Inc - Total Assets Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See ENSC book value for net asset value and shareholders' equity analysis.
Ensysce Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ensysce Biosciences Inc's total assets of $2.17 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.8% |
| Accounts Receivable | $420.35K | 5.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Ensysce Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Ensysce Biosciences Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ensysce Biosciences Inc's current assets represent 97.2% of total assets in 2025, an increase from 1.1% in 2017.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2025, up from 1.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
Ensysce Biosciences Inc Competitors by Total Assets
Key competitors of Ensysce Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Ensysce Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 2.50 | 2.07 |
| Quick Ratio | 0.71 | 2.50 | 2.07 |
| Cash Ratio | 0.00 | 1.73 | 1.99 |
| Working Capital | $-828.27K | $2.64 Million | $4.33 Million |
Ensysce Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Ensysce Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 33.1% |
| Total Assets | $7.45 Million |
| Market Capitalization | $3.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ensysce Biosciences Inc's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ensysce Biosciences Inc's assets grew by 33.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ensysce Biosciences Inc (2017–2025)
The table below shows the annual total assets of Ensysce Biosciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.45 Million | +33.15% |
| 2024-12-31 | $5.60 Million | +106.69% |
| 2023-12-31 | $2.71 Million | -53.98% |
| 2022-12-31 | $5.89 Million | -64.15% |
| 2021-12-31 | $16.42 Million | +4566.58% |
| 2020-12-31 | $351.81K | -99.82% |
| 2019-12-31 | $196.51 Million | -4.06% |
| 2018-12-31 | $204.83 Million | +1.19% |
| 2017-12-31 | $202.43 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more